Elanco Animal Health Incorporated Payments for Restructuring
Elanco Animal Health Incorporated (ELAN) reported Payments for Restructuring of $40.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-05
- Elanco Animal Health Incorporated payments for restructuring for the quarter ending 2026-06-30 was $19.00M.
- Elanco Animal Health Incorporated payments for restructuring for the quarter ending 2026-03-31 was $21.00M.
- Elanco Animal Health Incorporated payments for restructuring for the quarter ending 2023-09-30 was $1.00M.
- Elanco Animal Health Incorporated payments for restructuring for the quarter ending 2021-12-31 was $19.00M, a 32.14% decline year-over-year.
- Elanco Animal Health Incorporated payments for restructuring for fiscal 2025 was $10.00M, a 68.75% decline from fiscal 2024.
- Elanco Animal Health Incorporated payments for restructuring for fiscal 2024 was $32.00M.
- Elanco Animal Health Incorporated payments for restructuring for fiscal 2021 was $114.00M, a 159.09% increase from fiscal 2020.
- Elanco Animal Health Incorporated payments for restructuring for fiscal 2020 was $44.00M, a 38.80% increase from fiscal 2019.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 3 month as first filed | Payments for Restructuring 6 month | Payments for Restructuring 6 month as first filed | Payments for Restructuring 9 month | Payments for Restructuring 9 month as first filed | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $40.00M 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | $21.00M 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $10.00M 10-K · filed 2026-02-24 | |||||||
| 2024-12-31 | $32.00M 10-K · filed 2026-02-24 | |||||||
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $29.00M 10-Q · filed 2023-11-07 | ||||||
| 2023-06-30 | $28.00M 10-Q · filed 2023-08-07 | |||||||
| 2021-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $44.00M derived: sum of 2 quarters · filed 2022-02-28 | $76.00M derived: sum of 3 quarters · filed 2022-02-28 | $114.00M 10-K · filed 2022-02-28 | ||||
| 2021-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $57.00M derived: sum of 2 quarters · filed 2021-11-05 | $95.00M 10-Q · filed 2021-11-05 | $123.00M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2021-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $70.00M 10-Q · filed 2021-08-09 | $98.00M derived: sum of 3 quarters · filed 2022-02-28 | $100.00M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2021-03-31 | $38.00M 10-Q · filed 2021-05-07 | $66.00M derived: sum of 2 quarters · filed 2022-02-28 | $68.00M derived: sum of 3 quarters · filed 2022-02-28 | $71.00M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $30.00M derived: sum of 2 quarters · filed 2022-02-28 | $33.00M derived: sum of 3 quarters · filed 2022-02-28 | $44.00M 10-K · filed 2022-02-28 | $43.50M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $5.00M derived: sum of 2 quarters · filed 2021-11-05 | $16.00M 10-Q · filed 2021-11-05 | $16.20M 10-Q · filed 2020-11-06 | $26.90M derived: sum of 4 quarters · filed 2021-11-05 | |||
| 2020-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $14.00M 10-Q · filed 2021-08-09 | $13.80M 10-Q · filed 2020-07-30 | $24.90M derived: sum of 3 quarters · filed 2021-08-09 | $30.20M derived: sum of 4 quarters · filed 2021-08-09 | |||
| 2020-03-31 | $11.00M 10-Q · filed 2021-05-07 | $10.80M 10-Q · filed 2020-05-07 | $21.90M derived: sum of 2 quarters · filed 2021-05-07 | $27.20M derived: sum of 3 quarters · filed 2021-05-07 | $35.10M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.20M derived: sum of 2 quarters · filed 2021-03-01 | $24.10M derived: sum of 3 quarters · filed 2021-03-01 | $31.70M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $13.20M derived: sum of 2 quarters · filed 2020-11-06 | $20.80M 10-Q · filed 2020-11-06 | $36.20M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $15.50M 10-Q · filed 2020-07-30 | $30.90M derived: sum of 3 quarters · filed 2020-07-30 | $26.10M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | $7.60M 10-Q · filed 2020-05-07 | $23.00M derived: sum of 2 quarters · filed 2020-05-07 | $18.20M derived: sum of 3 quarters · filed 2020-05-07 | $36.20M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $10.60M derived: sum of 2 quarters · filed 2020-02-28 | $28.60M derived: sum of 3 quarters · filed 2020-02-28 | $48.90M 10-K · filed 2020-02-28 | ||||
| 2018-09-30 | -$4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $13.20M derived: sum of 2 quarters · filed 2019-11-08 | $33.50M 10-Q · filed 2019-11-08 | $115.50M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $38.30M 10-Q · filed 2019-08-13 | $120.30M derived: sum of 3 quarters · filed 2019-08-13 | |||||
| 2018-03-31 | $20.30M 10-Q · filed 2019-05-14 | $102.30M derived: sum of 2 quarters · filed 2019-05-14 | ||||||
| 2017-12-31 | $82.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $151.40M 10-K · filed 2019-02-20 | ||||||
| 2017-09-30 | $69.40M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |